Journal
RMD OPEN
Volume 8, Issue 2, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/rmdopen-2022-002387
Keywords
rheumatoid arthritis; biological therapy; therapeutics
Categories
Ask authors/readers for more resources
This review summarises the key concepts of difficult to treat rheumatoid arthritis (D2T-RA) defined by the European Alliance of Associations for Rheumatology. D2T-RA is primarily characterized by the failure of at least two different mechanism of action drugs with evidence of active/progressive disease. The review suggests additional considerations in the definition of D2T-RA and the potential value of identifying D2T traits and intervening before the development of D2T-RA state.
The European Alliance of Associations for Rheumatology recently defined difficult to treat (D2T) rheumatoid arthritis (RA) and provided points to consider in its management. This review summarises the key concepts of D2T-RA that underpinned this recent guidance. D2T-RA is primarily characterised by failure of at least two different mechanism of action biologic/targeted synthetic disease-modifying antirheumatic drug (DMARDs) with evidence of active/progressive disease. The basis for progressive disease, however, is not limited to clear inflammatory joint pathology, capturing wider contributors to treatment cycling such as comorbidity, obesity and fibromyalgia. This means D2T-RA comprises a heterogeneous population, with a proportion within this exhibiting bona fide treatment-refractory disease. The management points to consider, however, emphasise the importance of checking for the presence of inflammatory pathology before further treatment change. This review suggests additional considerations in the definition of D2T-RA, the potential value in identifying D2T traits and intervening before the development of D2T-RA state and the need for real world evidence of targeted synthetic DMARD in this population to compare to recent trial data. Finally, the review asks whether the presence of D2T-RA implies a failure to treat effectively from the outset, and the need for pharmacological and non-pharmacological management approaches to address the wider D2T-RA population effectively.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available